Children’s HIV vaccine poses complex questions
Scientists need to resolve how an HIV vaccine can be tested on children before the vaccine is ready for widespread human use, according to Professor Helen Rees, head of the Medicine Control Council (MCC).
The MCC has to give permission for drug and vaccine trials in this county.
“The primary target population for an HIV vaccine is children under the age of 14 [before they become sexually active],” said Rees.
“But human trials are usually conducted on adults, who are biologically and physiologically different from children,” said Professor Rees.
“If we wait to complete an adult trial, that will take five years. But if the vaccine has not been tested in children, there will be no safety data for children and it would be very difficult for the MCC to license the vaccine for use in children. But how do you start testing on children and babies?”
One option could be to start tests on high-risk groups – such as babies born to HIV positive mothers who were being breastfed, said Professor Rees.
While the scientists hope to begin human trials in the third quarter of this year, Professor Rees said that “we don’t want the regulatory process to be a barrier, but no one can prejudge the regulatory process”.
Give the caution with which the MCC has approached the licensing of Nevirapine for mother-to-child-transmission, it is quite possible that human trials may only begin next year.
Before approval is given for any human trials, the MCC has to review all science, protocols and ethics relating to the proposed trials.
The MCC, Medical Research Council and SA AIDS Vaccine Initiative (SAAVI) have also set up a reference group to review vaccine trial applications.
South Africa is one of a number of countries which has recently begun to grapple with problems associated with a vaccine, said Professor Rees.
The World Health Organisation (WHO) recently convened a meeting for scientists and regulatory authorities from a range of countries, including the USA, Britain, Uganda, Thailand and Kenya, to discuss how best to run vaccine trials.
The intention of the meeting was to review both the scientific knowledge relating to vaccines and the standards involved in evaluating a vaccine.
“We need to define what an effective vaccine is,” said Professor Rees. “Is it one that offers complete protection from HIV? Or do we accept a vaccine that allows some infection, but where the virus is not as aggressive? Do we accept a vaccine that is able to greatly reduce the viral load? And what is the effect of vaccinating people who are already HIV positive?”
Rees said participants at the WHO meeting were also concerned that international standards for measuring a vaccine’s efficacy needed to be set.
“Will the laboratories in different countries be able to maintain the same standards? And if we are measuring immune response, we need to ensure that there is an international standard. But what is a normal immune response?”
Participants also debated whether a person who became HIV positive as a result of being tested with the vaccine should be entitled to anti-retroviral drugs. It would also be difficult to know whether such a person became infected from the vaccine trial or from infection from another person.
Professor Rees added that, as many of the regulatory authorities in the developing world were weak, the WHO and the Joint United Nations Agency on AIDS (UNAIDS) were considering setting up a regulatory reference group to assist them to deal with these “complex problems”.
Author
Kerry Cullinan is the Managing Editor at Health-e News Service. Follow her on Twitter @kerrycullinan11
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Children’s HIV vaccine poses complex questions
by Kerry Cullinan, Health-e News
March 30, 2001